143 related articles for article (PubMed ID: 27042843)
1. Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors.
Anandi P; Jain NA; Tian X; Wu CO; Pophali PA; Koklanaris E; Ito S; Savani BN; Barrett J; Battiwalla M
Bone Marrow Transplant; 2016 Aug; 51(8):1101-6. PubMed ID: 27042843
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ
J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959
[TBL] [Abstract][Full Text] [Related]
3. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
[TBL] [Abstract][Full Text] [Related]
5. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
Tauchmanovà L; De Simone G; Musella T; Orio F; Ricci P; Nappi C; Lombardi G; Colao A; Rotoli B; Selleri C
Bone Marrow Transplant; 2006 Jan; 37(1):81-8. PubMed ID: 16247420
[TBL] [Abstract][Full Text] [Related]
6. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.
Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C
J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Grigg AP; Shuttleworth P; Reynolds J; Schwarer AP; Szer J; Bradstock K; Hui C; Herrmann R; Ebeling PR
J Clin Endocrinol Metab; 2006 Oct; 91(10):3835-43. PubMed ID: 16835281
[TBL] [Abstract][Full Text] [Related]
9. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Tauchmanovà L; Selleri C; Esposito M; Di Somma C; Orio F; Bifulco G; Palomba S; Lombardi G; Rotoli B; Colao A
Osteoporos Int; 2003 Dec; 14(12):1013-9. PubMed ID: 14517597
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
11. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP
J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
[TBL] [Abstract][Full Text] [Related]
13. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T
Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116
[TBL] [Abstract][Full Text] [Related]
15. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
16. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study.
Schulte C; Beelen DW; Schaefer UW; Mann K
Osteoporos Int; 2000; 11(4):344-53. PubMed ID: 10928225
[TBL] [Abstract][Full Text] [Related]
17. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years.
Haugeberg G; Ørstavik RE; Uhlig T; Falch JA; Halse JI; Kvien TK
Arthritis Rheum; 2002 Jul; 46(7):1720-8. PubMed ID: 12124854
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for reduced areal bone mineral density in young adults with stem cell transplantation in childhood.
Taskinen M; Kananen K; Välimäki M; Löyttyniemi E; Hovi L; Saarinen-Pihkala U; Lipsanen-Nyman M
Pediatr Transplant; 2006 Feb; 10(1):90-7. PubMed ID: 16499594
[TBL] [Abstract][Full Text] [Related]
19. Decreased bone mineral density is common after autologous blood or marrow transplantation.
Schimmer AD; Mah K; Bordeleau L; Cheung A; Ali V; Falconer M; Trus M; Keating A
Bone Marrow Transplant; 2001 Aug; 28(4):387-91. PubMed ID: 11571512
[TBL] [Abstract][Full Text] [Related]
20. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
